Needham initiated coverage of Atai Life Sciences (ATAI) with a Buy rating and $12 price target The firm believes the company’s BPL-003 could offer greater convenience than Spravato with potentially improved efficacy. BPL-003 is well positioned to leverage to logistics established by Spravato and expand the market, taking 20% share by 2035 with over $2.5B in sales, the analyst tells investors in a research note. Needham sees Atai Life unlocking value in the psychedelics market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences to Acquire Beckley Psytech
- Atai Life Sciences management to meet with Oppenheimer
- Cathie Wood’s ARK Investment buys 254.6K shares of Atai Life Sciences today
- Atai Life Sciences files automatic mixed securities shelf
- Atai Life Sciences files to sell 45.32M common shares for holders